OR WAIT 15 SECS
The bladder cancer space across the seven major markets of the US, France, Germany, Italy, Spain, the UK and Japan, is set to more than triple in size from $360 million in 2015 to around $1.17 billion by 2025, according to research and consulting firm GlobalData. The company’s latest report states that this growth will be driven by the increased incorporation of immunotherapies into treatment algorithms, the launch of new combination therapies, increased incident cases of bladder cancer across the seven major markets, and the introduction of the pipeline agents CG-0070, Vicinium and Cyramza. Historically the bladder cancer market has been highly generic, with Bacillus Calmette-Guerin (BCG) and chemotherapies dominating the landscape. However, with the launch of Tecentriq and the subsequent launch of other programmed cell death protein 1 (PD-1) modulators, bladder cancer treatment algorithms are expected to change during the forecast period. Although pipeline agents will reduce unmet needs, opportunities will remain. In the non-muscle invasive bladder cancer (NMIBC) setting, the late-stage pipeline agents CG-0070, Vicinium and Instiladrin are expected to provide viable alternatives to cystectomy. However, none of these are being explored in the first-line setting, where there remains an unmet need for a safer drug than BCG with higher cure rates, as well as treatment options for patients who are BCG-ineligible or intolerant.